References
- Parkinson’s Disease Foundation. Parkinson’s disease: an overview. Available at: http://www.pdf.org/AboutPD/index.cfm [last accessed 15 February 2007]
- National Institute of Neurological Disorders and Stroke. NINDS Parkinson’s disease information page. Available at: http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease_ backgrounder.htm [last accessed 15 February 2007]
- Marjama-Lyons JM, Koller WC. Parkinson’s disease. Update in diagnosis and symptom management. Geriatrics 2001;56: 24–30, 33
- National Institute of Neurological Disorders and Stroke. Introduction to Parkinson’s disease. Available at: http://my.webmd.com/content/article/6/1680_51746.htm [last accessed 15 January 2006]
- Clarke CE. Medical management of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002;72(Suppl 1):I22–7
- Hardie RJ, Lees AJ, Stern GM. On–off fluctuations in Parkinson’s disease. A clinical and neuropharmacological study. Brain 1984;107:487–506
- Sage JI, Mark MH. Drenching sweats as an off phenomenon in Parkinson’s disease: treatment and relation to plasma levodopa profile. Ann Neurol 1995;37:120–2
- Giuffrida R, Vingerhoets FJ, Bogousslavsky J, et al. Pain in Parkinson’s disease. Rev Neurol (Paris) 2005;161:407–18
- Goetz CG, Tanner CM, Levy M, et al. Pain in Parkinson’s disease. Mov Disord 1986;1:45–9
- Reardon KA, Shiff M, Kempster PA. Evolution of motor fluctuations in Parkinson’s disease: a longitudinal study over 6 years. Mov Disord 1999;14: 605–11
- Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 1989;39(11 Suppl 2):11–9
- Cedarbaum JM, Toy LH, Green-Parsons A. L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson’s disease patients with motor response fluctuations. Clin Neuropharmacol 1991;14:228–34
- Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 1997;25:657–62
- Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline [An update]. Clin Pharmacokinet 1997;33: 91–102
- Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004;19:426–32
- Clarke A, Johnson ES, Mallard N, et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm 2003;110:1257–71
- Korczyn AD, Brunt ER, Larsen JP, et al, for the 053 Study Group. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease. Neurology 1999;53:364–70
- Nuki G, Bresnihan B, Bear MB, et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:2838–46
- Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224–33
- Zelapar™ (selegiline hydrochloride) orally disintegrating tablets [prescribing information]. Costa Mesa, CA: Valeant Pharmaceuticals International; June 2006
- Tanabe K, Yokochi F, Hirai S, et al. A 75-year-old man with parkinsonism and delirium. No To Shinkei 1994;46:85–92
- Takanashi M, Urabe T, Ohta S, et al. A 73-year-old woman with familial Parkinson’s disease. No To Shinkei 1999;51: 1087–96
- Okuma Y, Hattori N, Nobukawa B, et al. A 74-year-old woman with parkinsonism and dementia who died four years after the onset. No To Shinkei 1998;50:671–82
- Clarke A, Brewer F, Johnson ES, et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 2003;110;1241–57
- Leopold NA, Kagel MC. Prepharyngeal dysphagia in Parkinson’s disease. Dysphagia 1996;11:14–22
- Fuh JL, Lee RC, Wang SJ, et al. Swallowing difficulty in Parkinson’s disease. Clin Neurol Neurosurg 1997;99:106–12
- Thomson F, Muir A, Stirton J, et al. Parkinson’s disease. Pharm J 2001;267:600–12
- Allain H, Destée A, Petit H, et al. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson’s disease. The French Lisuride Study Group. Eur Neurol 2000;44:22–30